대한의생명과학회지 (Biomedical Science Letters)

  • 제20권2호
  • /
  • Pages.85-95
  • /
  • 2014
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지

The GSK-$3{\beta}$/Cyclin D1 Pathway is Involved in the Resistance of Oral Cancer Cells to the EGFR Tyrosine Kinase Inhibitor ZD1839

  • Jeon, Nam Kyeong (Seegene Institute of Life Sciences) ;
  • Kim, Jin (Department of Oral Pathology, Oral Cancer Research Institute, BK21 Project for Medical Science, Yonsei University College of Dentistry) ;
  • Lee, Eun Ju (Department of Clinical Laboratory Science, Daejeon Health Science College)
  • 투고 : 2014.06.18
  • 심사 : 2014.06.30
  • 발행 : 2014.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Activation of the epidermal growth factor receptor (EGFR) and downstream signaling pathways have been implicated in causing resistance to EGFR-targeted therapy in solid tumors, including the head and neck tumors. To investigate the mechanism of antiproliferation to EGFR inhibition in oral cancer, we compared EGFR tyrosine kinase inhibitor (Gefitinib, Iressa, ZD1839) with respect to its inhibitory effects on three kinases situated downstream of EGFR: MAPK, Akt, and glycogen synthase kinase-$3{\beta}$ (GSK-$3{\beta}$). We have demonstrated that ZD1839 induces growth arrest and apotosis in oral cancer cell lines by independent of EGFR-mediated signaling. An exposure of oral cancer cells to ZD1839 resulted in a dose dependent up-regulation of the cyclin-dependent kinase inhibitor p21 and p27, down regulation of cyclin D1, inactivation of GSK-$3{\beta}$ and of active MAPK. In resistant cells, GSK-$3{\beta}$ is constitutively active and its activity is negatively regulated primarily through Ser 9 phosphorylation and further enhanced by Tyr216 phosphorylation. These results showed that the resistance to the antiproliferative effects of ZD1839, in vitro was associated with uncoupling between EGFR and MAPK inhibition, and that GSK-$3{\beta}$ activation and degradation of its target cyclin D1 were indicators of high cell sensitivity to ZD1839. In conclusion, our data show that the uncoupling of EGFR with mitogenic pathways can cause resistance to EGFR inhibition in oral cancer.

키워드

참고문헌

  1. Benzeno S, Diehl JA. C-terminal sequence direct cyclin D1-CRM1 binding. J Biol Chem. 1999. 279: 56061-56066.
  2. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Eng J Med. 2011. 364: 947-955. https://doi.org/10.1056/NEJMct0807960
  3. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RASdependent manner. Cancer Res. 2002. 62: 4307-4315.
  4. Chang GC, Hsu SL, Tsai JR, Liang FP, Lin SY, Sheu GT, Chen CY. Molecular mechanism of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharm. 2004. 68: 1453-1464. https://doi.org/10.1016/j.bcp.2004.06.006
  5. Charles JS, James MR. CDK inhibitos: positive and negative regulator of G1-phase progression. Genes Dev. 1999. 13: 1501-1512. https://doi.org/10.1101/gad.13.12.1501
  6. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. The p21(cip1) and p27(kip1) 'CDK inhibitor's are essential activator of cyclin D-dependent kinase in murine fibroblast. EMBO J. 1999. 18: 1571-1583. https://doi.org/10.1093/emboj/18.6.1571
  7. Cheong SC, Chandramouil GV, Saleh A, Zain RB, Lau SH, Sivakumaren S, Pathmanathane R, Primef SS, Teoa SH, Patelg V, Gutkindg JS. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol. 2009. 45: 712-719. https://doi.org/10.1016/j.oraloncology.2008.11.002
  8. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res. 2000. 6: 2053-2063.
  9. Cunnick JM, Dorsey JF, Standley T, Turkson J, Kraker AJ, Fry DW, Jove R, Wu J. Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stmulated mitogen-activited protein kinase pathway. J Biol Chem. 1998. 273: 14468-14475. https://doi.org/10.1074/jbc.273.23.14468
  10. Farr GH 3rd, Ferkey DM, Yost C, Pierce SB, Weaver C, Kimelman D. Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol. 2000. 148: 691-702. https://doi.org/10.1083/jcb.148.4.691
  11. Gossage L, Eisen T. Targeting Multiple Kinase Pathways: A change in Paradigm. Clinical Cancer Research. 2010. 16: 1973-1978. https://doi.org/10.1158/1078-0432.CCR-09-3182
  12. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between Epidermal Growth Factor Receptor and Down-stream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells. Cancer Res. 2005. 65: 10524-10535. https://doi.org/10.1158/0008-5472.CAN-05-1536
  13. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003. 53: 5-26. https://doi.org/10.3322/canjclin.53.1.5
  14. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. New function activaties for the p21 family of CDK inhibitors. Genes Dev. 1997. 11: 847-862. https://doi.org/10.1101/gad.11.7.847
  15. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a pro-mising target in solid tumours. Cancer Treat Rev. 2004. 30: 1-17. https://doi.org/10.1016/j.ctrv.2003.10.002
  16. Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, Yook JI. Characterization of newly established oral cancer cell lines derived fromsix squamous cell carcinoma and two mucoepidermoid carcinoma cells. Exp Mol Med. 2005. 37: 379-390. https://doi.org/10.1038/emm.2005.48
  17. Lee EJ, Whang, JH, Jeon, NK, Kim J. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Annals NYAS. 2007. 1095: 113-128.
  18. Mishra A, Bharti AC, Saluja D, Das BC. Transactivation and expression patterns of Jun and Fos/AP-1 super family protein in human oral cancer. Int J Cancer. 2010. 126: 819-829.
  19. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Molecular Cancer. 2010. 9: 114. https://doi.org/10.1186/1476-4598-9-114
  20. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009. 45: 324-334. https://doi.org/10.1016/j.oraloncology.2008.07.011
  21. Nicolle G, Daher A, Maille P, Vermy M, Loric S, Bakkar A, Bakkar A, Wallerand H, Vordos D, Vacherot F, de Medina SG, Abbou CC, Van der Kwast T, Thiery JP, Radvanyi F, Chopin DK. Gefitinib inhibits the growth invasion of urothelial carcinoma cell lines in which Akt and MAPK Activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res. 2006. 12: 2937-2943. https://doi.org/10.1158/1078-0432.CCR-05-2148
  22. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem. 2000. 275: 22583-22589. https://doi.org/10.1074/jbc.M002915200
  23. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol. 2001. 21: 6387-6394. https://doi.org/10.1128/MCB.21.19.6387-6394.2001
  24. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A. Targeted inhibition of the epidermal growth factor receptor-tyrosin kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physio. 2004. 201: 97-105. https://doi.org/10.1002/jcp.20045
  25. Shintani S, Li C, Mihara M, Yano J, Terakado N, Nakashiro K, Hamakawa H. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncology. 2004. 40: 43-51.
  26. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007. 6: 277-285. https://doi.org/10.1158/1535-7163.MCT-06-0513
  27. Sirotnak FM. Studies with ZD1839 in preclinical model. Semin Oncol. 2003. 1: 12-20.
  28. Turenne GA, Price BD. Glycogen synthase kinase 3${\beta}$ phosphorylates serine 33 of p53 and activated p53' transcriptional activity. BMC Cell Biol. 2001. 2: 12. https://doi.org/10.1186/1471-2121-2-12
  29. Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical Pharmacokinetics of tyrosin kinase inhibitors. Cancer Treat Rev. 2009. 35: 692-706. https://doi.org/10.1016/j.ctrv.2009.08.004
  30. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally activive inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002. 62: 5749-5754.
  31. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1,independent of p53. J Bio Chem. 2004. 16: 16000-16006.